The IL-1 family in tumorigenesis and antitumor immunity. (November 2022)

• Record Type: Journal Article
• Authors: Sun, Runzi; Gao, David Shihong; Shoush, Jason; Lu, Binfeng
• Is Part Of: Seminars in cancer biology. Volume 86(2023)Part 2
• Page Start: 280
• Page End: 295
• Publication Date: 2022-11
• Subjects: IL-1 -- IL-18 -- IL-33 -- IL-36 -- Tumorigenesis -- Anti-tumor immune response; Cancer -- Periodicals; Neoplasms -- Periodicals; Review Literature; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.semcancer.2022.05.002
• Languages: English
• ISSNs: 1044-579X

Abstract

Abstract: The IL-1 family of cytokines consists of IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, and IL-36γ. These proteins form four signaling receptor complexes: the IL-1 receptor (IL-1R1 and IL-1RAcP), the IL-18 receptor (IL-18Rα and IL-18Rβ), the IL-33 receptor (ST2 and IL-1RAcP), and the IL-36 receptor (IL-1Rrp2 and IL-1RAcP). The formation of receptor complexes is also regulated by various antagonistic molecules and decoy receptors. The IL-1 family cytokines are induced and secreted by both innate immune cells and tissue cells upon infection and tissue damage. Thus, they play a diverse role in mediating both innate and adaptive immune responses. During tumor development and cancer treatment, the expression of the IL-1 gene family is differentially regulated in tumor cells, tissue stromal cells, and immune cells in a stage specific and tissue specific manner. Like other cytokines, the IL-1 family proteins have pleiotropic functions that are dependent on diverse arrays of target cells. As a result, they play a complex role in tumorigenesis, cancer metastasis, immune suppression, and cancer immune surveillance. Here, we focus on reviewing experimental evidence demonstrating how members of the IL-1 family influence cancer development at the cellular and molecular level. The unique mechanisms of this group of cytokines make them attractive targets for new cancer therapy.